Shares of Inovio (INO) gained 22.8% in premarket trading on Wednesday after the company said its COVID-19 vaccine candidate demonstrated neutralizing antibodies in animals. The data, published in Nature Communications (), is from a preclinical study, meaning it does not include information about how the investigational vaccine reacts in humans but in mice and guinea pigs. Inovio is currently conducting a Phase 1 clinical trial testing the DNA vaccine candidate in people; early data from that study is expected to be announced in June. "The potent neutralizing antibody and T cell immune responses generated in multiple animal models are supportive of our currently on-going INO-4800 clinical trials," Dr. Kate Broderick, Inovio's team lead for COVID-19 vaccine development, said in a news release. There are no proven vaccines that prevent against infections with COVID-19. Moderna Inc. (MRNA)announced early positive results ( ) from its Phase I trial testing a vaccine candidate in people on Monday. Inovio's stock is up 341.2% year-to-date, while the S&P 500 is down 9.5%.
-Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com
(END) Dow Jones Newswires
May 20, 2020 07:31 ET (11:31 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.